CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Résumé de cet Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Couture, P.
Right arrow Articles by Tardif, J.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Couture, P.
Right arrow Articles by Tardif, J.-C.
Canadian Journal of Anesthesia 54:509-522 (2007)
© Canadian Anesthesiologists' Society, 2007

Reports of Original Investigations

Milrinone enhances systolic, but not diastolic function during coronary artery bypass grafting surgery

[La milrinone améliore la fonction systolique mais non la fonction diastolique pendant la chirurgie de pontage aortocoronarien]

Pierre Couture, MD FRCPC*, André Y. Denault, MD FRCPC*, Michel Pellerin, MD FRCPS{dagger} and Jean-Claude Tardif, MD FRCPC{ddagger}

* From the Departments of Anesthesiology,
{dagger} Cardiac Surgery, and
{ddagger} Medicine, Montreal Heart Institute, University of Montréal, Montréal, Québec, Canada.

Address correspondence to: Dr. Pierre Couture, Department of Anesthesiology, Montreal Heart Institute, 5000 Bélanger St. East, Montréal, Québec H1T1C8, Canada. Phone: 514-376-3330, ext. 3732; Fax: 514-376-1355; E-mail: pierre.couture{at}icm-mhi.org Supported by Dr. Earl Wynands Research Award in Cardiovascular Anesthesia, 2001.

Purpose: To evaluate the effect of milrinone on diastolic function during coronary artery bypass grafting surgery (CABG).

Methods: Fifty patients undergoing CABG were randomized to receive a bolus and infusion of milrinone or placebo before cardiopulmonary bypass (CPB) until skin closure. Hemodynamic and transesophageal echocardiographic measurements of systolic and diastolic function were obtained. Pulsed wave Doppler measurements of the early (E wave) and atrial components (A wave) of the transmitral (TMF) and transtricuspid (TTF) flows, and systolic (S wave), diastolic (D wave) and atrial components (Ar) of the pulmonary (PVF) and hepatic venous blood flow (HVF) velocities were performed. Early and atrial components of the mitral (Em and Am waves) and tricuspid annulus velocities (Et and At waves) were assessed by tissue Doppler imaging (TDI). Assessment of diastolic dysfunction was graded from normal to severe using a scale score.

Results: Cardiac index and heart rate were higher in the milrinone group compared to placebo after the administration of study drug (2.8 ± 0.6 vs 2.1 ± 0.5 L·min–1m–2) (P < 0.0001) and (67 ± 8 vs 60 ± 12 beats·min–1) (P < 0.05) respectively. There were no changes in left and right ventricular diastolic dysfunction scores between study groups. Higher PVF S wave, HVF S wave, TTF A wave and At measured by TDI in the milrinone group compared with placebo suggested an improvement in ventricular systolic and atrial contraction.

Conclusion: Distinct from its effects on systolic function, milrinone administered before CPB is not with associated improved biventricular diastolic function in patients undergoing CABG.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Canadian Anesthesiologists' Society.